A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation.

"CONFLICTS OF INTEREST Guarantor of the article: Catherine Datto, MD, MS. Specific author contributions: D.M.B., Y.H., C.D., and M.C. were involved in the study planning, interpretation of the data, and development of the manuscript. D.C. was involved in the interpretation of the data and development of the manuscript. All authors approved the final submitted draft of this manuscript. Financial support: This research was funded by AstraZeneca Pharmaceuticals LP (Wilmington, DE, USA). The named authors, which included AstraZeneca employees, were involved in the study design; in the collection, analysis, and interpretation of data; in writing the report; and in the decision to submit the article for publication. Megan Knagge, PhD, of MedErgy (Yardley, PA, USA) provided medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines and funded by AstraZeneca (Wilmington, DE, USA). Potential competing interests: D.M.B. has served as a speaker/advisor for AstraZeneca, Daiichi Sankyo, Salix, and Shionogi Pharmaceuticals. Y.H., C.D., and D.C. are employees of AstraZeneca. M.C. received a research grant from AstraZeneca for a study on the pharmacodynamics of naloxegol treatment, published in PMID 29405492. Clinical trial registration:ClinicalTrials.gov identifier: NCT03060512.Study HighlightsWHAT IS KNOWN✓ A common side effect of opioid use in individuals with noncancer pain is constipation.✓ OTC laxatives are recommended as first-line therapy for OIC.✓ Patient preferences for OIC treatment, particularly prescription vs OTC laxatives, are poorly understood.WHAT IS NEW HERE✓ In this first head-to-head study, patients with noncancer pain reported similar preference rates and strong preferences for naloxegol or PEG 3350.✓ Preference for naloxegol or PEG 3350 was associated with clinical improvements on the BFI and PGIC in patients with OIC.✓ Among patients aged <50 years or receiving laxatives within the previous 2 weeks, a numerically greater proportion preferred naloxegol."

"Financial support: This research was funded by AstraZeneca Pharmaceuticals LP (Wilmington, DE, USA). The named authors, which included AstraZeneca employees, were involved in the study design; in the collection, analysis, and interpretation of data; in writing the report; and in the decision to submit the article for publication. Megan Knagge, PhD, of MedErgy (Yardley, PA, USA) provided medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines and funded by AstraZeneca (Wilmington, DE, USA)."